Lipoxins: regulators of resolution.
Persistent inflammation underlies many prevalent diseases including atherosclerosis and diabetes. There is a growing appreciation that inflammation and its active resolution may be modulated by endogenously produced lipids. Pre-eminent amongst these mediators are lipoxin [LX]A4 and LXB4. The LXs are eicosanoids and display both anti-inflammatory and pro-resolving bioactions. In effective host defence lipid mediator biosynthesis is characterised by a switch from pro-inflammatory prostaglandin and leukotriene (LT) generation from arachidonic acid (AA) to LX production coincident with a return to tissue homeostasis. There is accumulating evidence that LXs are potential therapeutic agents for inflammatory disorders leading to tissue damage and organ fibrosis.
Ryan
Aidan
A
Diabetes Research Centre, Conway Institute and School of Medicine and Medical Science, University College Dublin, Belfield, Dublin 4, Ireland.
Godson
Catherine
C
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use*; D050197:Atherosclerosis / Q000378:metabolism; D042783:Endothelial Cells / Q000187:drug effects / Q000378:metabolism; D005921:Glomerulonephritis / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D044045:Lipoxins / Q000096:biosynthesis / Q000378:metabolism* / Q000627:therapeutic use*; D008954:Models, Biological; D009393:Nephritis / Q000188:drug therapy* / Q000378:metabolism
D000893:Anti-Inflammatory Agents; D044045:Lipoxins